(BUSINESS WIRE)--Alkermes, Inc. will provide an overview of upcoming milestones for its commercial products, late-stage product candidates and emerging clinical candidates from the company’s proprietary pipeline on Monday, January 10, 2011, at the 29th Annual JPMorgan Healthcare Conference in San Francisco. Highlights include the expansion of the ALKS 33 clinical program into treatment-resistant depression (TRD) and the presentation of interim data from the VIVITROL® (naltrexone for extended-release injectable suspension) phase 4 study in healthcare professionals with opioid dependence.
